Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127569 | 0.88 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL15014144 | 0.86 | LMNA (0.53) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL11522683 | 0.85 | LOXL2 (0.53) | CYP4F2CYP4A11ALDH1A1RAB9ALMNA | |
| SCHEMBL3236449 | 0.85 | MAPT (0.65) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL32685467 | 0.85 | MAPT (0.65) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL4926537 | 0.84 | CYP4F2 (0.52) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL14898280 | 0.84 | LMNA (0.49) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL10106410 | 0.84 | PTPN1 (0.58) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL14879820 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL10106391 | 0.83 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1342719-B1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | FERRING BV (NL) | 2011-04-13 | — | — | EP | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-1342719-A1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-5962451-A | GASTROINTESTINAL DISORDERS; ANTIULCER AGENT; ANTICANCER AGENTS; SIDE-EFFECT REDUCTION | FERRING BV (NL) | 1999-10-05 | — | — | US | disclosed |
| US-5688943-A | CHOLECYSTOKININ ANTAGONIST; ANTIULCER AGENTS; PSYCHOLOGICAL DRUGS; ANXIOLYTIC AGENTS; CONTROLLING APPETITE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0628033-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016999-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-09-02 | — | — | WO | disclosed |
| CN-1075717-A | Benzodiazepine * derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-09-01 | — | — | CN | disclosed |
| US-3971821-A | Production of aminobenzaldehydes | BASF AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CYP4F2 2423/4885CYP4A11 619/4885ALDH1A1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.